Cell Salvage: The Most Underused Tool in Australian Surgery

Here's something that still surprises me after 20 years in this business.

Cell salvage is one of the most effective interventions in patient blood management. It reduces the need for allogeneic transfusion. It's recommended in the National Blood Authority's Patient Blood Management Guidelines. The evidence base is extensive and consistent.

And yet in many hospitals across Australia, it's still treated as a nice-to-have rather than a standard of care.

What is cell salvage?

For those outside the perfusion world: cell salvage (also called autotransfusion or intraoperative blood salvage) is the process of collecting a patient's own blood lost during surgery, washing and concentrating it, and giving it back to them. The patient gets their own red cells returned rather than receiving blood from a donor.

The concept is simple. The execution requires trained operators and the right equipment, but it's not complicated. We've been doing it for decades.

The case for cell salvage

The clinical argument is well established. Every unit of allogeneic blood transfused carries risks, transfusion reactions, immunomodulation, infection transmission, and increased length of stay. The National Blood Authority's guidelines are clear: avoid unnecessary transfusion. Cell salvage is one of the most direct ways to achieve that.

The financial argument is equally compelling. A unit of allogeneic red cells costs the health system hundreds of dollars before you factor in testing, storage, administration, and the management of transfusion-related complications. Cell salvage, particularly in cases with predictable blood loss, can significantly reduce that cost.

And the patient argument? It's the strongest of all. Patients who receive their own blood back avoid the risks associated with donor blood entirely. For patients who decline allogeneic transfusion for religious or personal reasons, cell salvage can be the difference between proceeding with surgery and not.

So why isn't it everywhere?

I've lost count of the number of times a surgeon has said to me "I didn't know that was an option" when we've offered cell salvage on a case with predictable blood loss. Orthopaedic revisions. Major spinal surgery. Liver resections. Obstetric haemorrhage. These aren't edge cases, they're bread and butter surgery.

The barrier isn't evidence. It's awareness and access.

Many hospitals simply don't have trained autotransfusion staff on site. Some have the equipment but not the expertise. Others have neither and assume cell salvage is only relevant for cardiac surgery. It's not. The applications extend well beyond the cardiac theatre, and the threshold for when it becomes clinically and financially worthwhile is lower than most people assume.

What we've seen at ABM

We've been providing outsourced cell salvage services since ABM started in 2006. In that time, we've watched the demand grow steadily as more surgeons, anaesthetists, and blood bank managers recognise the value.

The pattern is almost always the same. A hospital brings us in for a trial on a specific list, usually complex ortho or spine. They see the results: reduced transfusion, reduced costs, happy patients, happy surgeon. Then they want us on more lists. Then they start wondering why they weren't doing this years ago.

The answer, usually, is that nobody had offered it.

Making it happen

If you're in a hospital that doesn't currently have a cell salvage service, here's the good news: you don't need to build one from scratch. Companies like ours exist specifically to provide trained autotransfusion specialists, equipment, and consumables as a turnkey service. We integrate with your existing theatre workflow, manage the equipment, and handle the clinical operation.

If you're a surgeon, ask your blood bank or transfusion committee whether cell salvage is available for your lists. If it's not, ask why not.

If you're in procurement or hospital management, look at your transfusion data. If you're buying blood you don't need to buy, there's a conversation to be had.

And if you're a perfusionist or autotransfusionist looking for more diverse caseload — this is the growth area. The demand is there. The evidence supports it. The only missing piece is people who can deliver the service.

The bottom line

Cell salvage saves blood, saves money, and improves patient outcomes. The evidence is there. The guidelines recommend it. The technology is proven. The only thing holding it back in Australia is access to trained people and equipment.

That's exactly the problem ABM was built to solve. If your hospital should be doing more with cell salvage, let's talk.